Recently, the addition of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, to this regimen has demonstrated improved survival outcomes [5], underscoring the potential of immunotherapy in CCA. This evidence concerns the gene CD274 and cholangiocarcinoma.